Safety and Anti-leukemic Activity of Vodobatinib (K0706) for Treatment of Ph+ CML Resistant/Intolerant to ≥3 Prior CML Therapies

Inclusion Criteria: * Willing and able to give written, and dated, informed consent * Male or female aged ≥ 18 years * Willing and able to comply with the scheduled visits * Eastern Cooperative Oncology Group (ECOG) performance status of 0, 1, or 2 * Subjects diagnosed with Ph+ CML-CP, Ph+ CML-AP, Ph+ CML-BP, who are resistant and/or intolerant to ≥ 3 prior TKIs one of which includes ponatinib (Part C). Exclusion Criteria: * Presence of T315I (PART C) * Any major surgery, as determined by the Investigator, within 4 weeks of IMP administration * Inability to undergo venipuncture and/or tolerate venous access * Positive exclusion tests: urine pregnancy tests (if applicable), HIV, hepatitis B surface antigen, or hepatitis C virus * Known or suspected history of significant drug abuse as judged by the Investigator * Received any other investigational agent within 30 days or a washout of at least 5 half-lives, whichever is longer of IMP administration * Subjects who are eligible for potentially curative therapy that is available, including hematopoietic stem cell transplant * Another primary malignancy within the past 3 years or earlier (except for adequately treated non-melanoma skin cancer or cervical cancer in situ